Patents by Inventor Nagarathanam Veerasamy

Nagarathanam Veerasamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20230330099
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 19, 2023
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Substituted indole Mcl-1 inhibitors
    Patent number: 11596639
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 7, 2023
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20210283138
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 16, 2021
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian